MedTech Startup Funding

What are all the funding deals in the MedTech market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play MedTech companies between August 2025 and July 2026. We count as “pure-play” MedTech companies those focused on medical devices, diagnostic devices, surgical tools, connected medical devices, hospital equipment, implantable devices, and device-specific data platforms.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source.

How active has fundraising been in the MedTech market?

As of July 2026, fundraising in the MedTech market has been active and substantial. Over the past 12 months, companies raised 52 disclosed equity rounds and $3.13B combined, which works out to 4.33 deals per month.

The MedTech market was not a single-month story. The median month had 5 deals, and April 2026 alone produced 8 verified rounds, the highest monthly count in the dataset.

Capital flow was more uneven than deal flow. Average capital raised per month was $261.1M, while the median was $282.0M, showing that several large months shaped the annual total.

The weakest visible month was October 2025, with no verified qualifying deals. That does not mean MedTech activity stopped; it means public disclosed equity announcements were lumpy.

How concentrated has fundraising been in the MedTech market?

As of July 2026, fundraising in the MedTech market is concentrated, but not captured by one outlier. Over the past 12 months, the largest deal accounts for 8.0% of capital, the top 3 reach 21.8%, and the top 5 reach 31.6%.

The top 10 deals account for 51.0% of all disclosed capital in the MedTech market. That means half of the market’s funding signal comes from ten companies, but the other half is still spread across 42 deals.

This is a healthier concentration pattern than a single-winner market. Synchron, Science Corp, Merge Labs, Impulse Dynamics, Distalmotion, SetPoint Medical, Endogenex, Apreo Health, GT Medical Technologies, and Pulnovo Medical all contribute meaningfully.

The better reading is that MedTech has clustered conviction. Investors are not backing everything evenly, but they are funding several validated device platforms rather than one dominant company.

How much of the MedTech funding signal is driven by outliers?

As of July 2026, the MedTech funding signal is meaningfully shaped by outliers, but not fully dependent on them. Over the past 12 months, 23 rounds were $50M or larger, and 8 rounds were above $100M.

Megarounds above $50M represent 42.3% of all deals in the MedTech market. That is high for a regulated hardware market, and it shows how expensive pivotal trials, commercialization, and manufacturing scale can become.

Removing rounds above $50M leaves $673.6M in disclosed capital. That remaining pool is still meaningful, but it is far smaller than the $3.13B headline total.

The median round was $40.0M, while the average was $60.3M. This gap confirms that larger rounds pull the average upward, so the median is the better read on the typical visible financing.

Is the MedTech market broad with many targets, or narrow with few fundable companies?

As of July 2026, the MedTech market looks broad in company count but selective in capital allocation. Over the past 12 months, the dataset includes 52 unique companies, with no company appearing twice.

That company breadth matters. Unlike markets where repeat fundraisers dominate the visible dataset, this MedTech sample shows a wide set of independent device and device-platform companies raising capital.

Capital, however, is not spread equally across the market. Implantable Devices alone captured 50.5% of total capital, even though it represented only 34.6% of deals.

The MedTech market is therefore broad at the company level but narrower at the conviction level. Investors saw many fundable targets, but larger checks clustered around implantable, procedural, and clinically validated platforms.

Is MedTech mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the MedTech market is mostly a late-stage scaling and validation market. Over the past 12 months, Series C, Series D+, and growth equity rounds raised $2.15B, or 68.7% of disclosed capital.

Series C was the largest stage by capital, with $888.0M across 12 deals. That makes mid-late clinical development and early commercialization the center of gravity for the MedTech market.

Series A still tied Series C on deal count, with 12 disclosed rounds. That means new company formation continued, even though most dollars went to companies that had already cleared early technical or clinical hurdles.

Seed-stage statistics need caution. Seed rounds raised $265.8M, but Merge Labs’ $252M seed round overwhelms the category, while the seed median was only $11.0M.

Which categories attract the most investor attention in MedTech?

As of July 2026, Implantable Devices and Medical Devices attract the most investor attention in MedTech. Together they account for 32 of 52 deals and $2.44B raised over the past 12 months.

Implantable Devices leads the MedTech market with $1.58B raised across 18 deals. The category represents 50.5% of all capital and 34.6% of all disclosed deals.

Medical Devices ranks second with $861.6M raised across 14 deals. This category includes large vascular, pulmonary, metabolic, oncology, and device-materials platforms.

Surgical Tools produced 8 deals and $345.7M. That is a smaller capital pool, but still meaningful because robotic surgery, navigation, HIFU, colorectal surgery, and kidney stone systems all require specialized procedural adoption.

Which categories attract disproportionately large checks in the MedTech market?

As of July 2026, Implantable Devices attract the most disproportionately large checks in the MedTech market. Over the past 12 months, the category had a capital share of 50.5% and a deal share of 34.6%, giving it a capital-to-deal share ratio of 1.46.

That ratio matters because it shows where investors are paying a premium per deal. Implantable Devices include brain-computer interfaces, neurostimulation, cardiac devices, urology implants, vascular implants, and radiotherapy implants.

Medical Devices sit close to parity, with a capital-to-deal share ratio of 1.02. That suggests the category is large, but not unusually overfunded relative to its deal count.

Diagnostic Devices are the opposite case. They represent 7.7% of deals but only 1.6% of capital, which suggests pure diagnostic-device rounds remain smaller unless tied to a larger hardware or reimbursement platform.

Which geographies matter most for fundraising in the MedTech market?

As of July 2026, North America is the geography that matters most for MedTech fundraising. Over the past 12 months, it captured $2.59B across 41 disclosed deals, equal to 82.7% of total capital.

Europe was the second-largest region, with $522.2M across 10 deals. Its deal share was 19.2%, but its capital share was 16.7%, which means average check size was lower than North America.

The Middle East contributed one disclosed MedTech round. Butterfly Medical raised $21.0M, equal to 0.7% of disclosed capital and 1.9% of deal count.

North America’s advantage is both breadth and scale. It had more companies, more large rounds, and a higher average round size than Europe.

Is the MedTech opportunity set broad or concentrated in one hub?

As of July 2026, the MedTech opportunity set is broad within North America but geographically concentrated overall. Over the past 12 months, North America accounted for 78.8% of deals and 82.7% of disclosed capital.

Europe is clearly present, but it does not set the funding tempo. Its strongest companies in the dataset tend to be surgical or implantable platforms, including Distalmotion, ViCentra, ProVerum Medical, UroMems, and Neurent Medical.

The Middle East appears through one company only. That makes it visible in the dataset but not yet a scaled funding hub for the MedTech market.

The practical conclusion is that MedTech remains a North America-led funding market. Europe has meaningful regulated-hardware innovation density, but the largest visible checks still skew heavily toward North American companies.

Is MedTech a market of small experiments or scaled financings?

As of July 2026, the MedTech market is much closer to a scaled-financing market than a market of small experiments. Over the past 12 months, 23 of 52 rounds were $50M or larger.

The size distribution is telling. Only 1 round was below $5M, 11 rounds were between $5M and $20M, 17 rounds were between $20M and $50M, and 23 rounds were above $50M.

The median round was $40.0M, which is already large compared with many software markets. In MedTech, that size often reflects clinical trials, regulatory work, manufacturing preparation, and commercialization hiring.

Rounds above $100M were less common but still important. The dataset includes 8 of them, representing 15.4% of all disclosed deals and setting much of the market’s headline narrative.

Who are the investors that appear the most in MedTech fundraising?

As of July 2026, repeat investors in the MedTech market are present but not highly concentrated. Over the past 12 months, only eight named investors appeared in more than one disclosed deal in the dataset.

The repeat investor list includes S3 Ventures, Vensana Capital, Sherpa Healthcare Partners, Gilde Healthcare, MVM Partners, U.S. Venture Partners, Santé Ventures, and MedVenture or MedVenture Partners. Each appeared in two disclosed deals.

This pattern suggests that MedTech investing remains specialist-driven. Investors need technical, regulatory, clinical, and reimbursement expertise, so repeat appearances often come from firms built around regulated healthcare hardware.

One important caveat is that round announcements rarely disclose each investor’s individual check size. The repeat count should therefore be read as participation frequency, not dollars personally committed by each investor.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.